PMID- 30307414
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Linking)
VI  - 30
IP  - 6
DP  - 2018 Nov
TI  - Allogeneic hematopoietic stem-cell transplantation from haploidentical donors 
      using 'ex-vivo' T-cell depletion in pediatric patients with hematological 
      malignancies: state of the art review.
PG  - 396-401
LID - 10.1097/CCO.0000000000000480 [doi]
AB  - PURPOSE OF REVIEW: Nowadays, T-cell-depleted haploidentical transplantation is 
      considered a valid approach for children lacking a human leukocyte antigen (HLA) 
      identical donor for allogeneic transplantation. This kind of allogeneic 
      transplant is now widely used especially for pediatric patients with high-risk 
      hematological malignancies. However, relapsing disease and life-threatening viral 
      infections are still relevant clinical problems as a consequence of delayed 
      immune reconstitution. Adoptive cell therapies have been proposed to overcome 
      this problem. RECENT FINDINGS: After initial clinical approach using CD34+ 
      selection as method for T-cell depletion (TCD), it was observed that immune 
      reconstitution was delayed and it resulted on high incidence of opportunistic 
      infections and nonrelapse mortality. It is now evident that development over time 
      of graft manipulation techniques for TCD, have provide clinicians a useful tool 
      for overcoming transplant complication such as graft failure, severe 
      graft-vs.-host disease and opportunistic infections. As such, several procedures 
      of almost total or partial TCD have been developed including CD3/CD19 depletion, 
      T cell receptor alphabeta/CD19 depletion and more recently CD45RA+ depletion. Recent 
      studies showed that immune reconstitution is associated with transplant outcomes. 
      Based on this, haploidentical transplantation is now been explored as platform 
      for cellular therapy to prevent disease recurrence or to treat clinical 
      complications. SUMMARY: Allogeneic transplantation still remains a standard of 
      care for pediatric patients with high-risk hematological malignancies. In absence 
      of an HLA identical donor, T-cell-depleted haploidentical transplant is now 
      considered a valid option and provide a platform for cellular therapy to prevent 
      relapse disease or to treat opportunistic infections.
FAU - Gonzalez-Vicent, Marta
AU  - Gonzalez-Vicent M
AD  - Stem Cell Transplant Unit, Hospital Nino Jesus, Madrid, Spain.
FAU - Diaz Perez, Miguel A
AU  - Diaz Perez MA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
SB  - IM
MH  - Child
MH  - Hematologic Neoplasms/immunology/*therapy
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*methods
MH  - Humans
MH  - Lymphocyte Depletion/*methods
MH  - T-Lymphocytes/*immunology
MH  - Transplantation Immunology
MH  - Transplantation, Haploidentical/*methods
MH  - Transplantation, Homologous
EDAT- 2018/10/12 06:00
MHDA- 2019/05/06 06:00
CRDT- 2018/10/12 06:00
PHST- 2018/10/12 06:00 [entrez]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2019/05/06 06:00 [medline]
AID - 00001622-201811000-00007 [pii]
AID - 10.1097/CCO.0000000000000480 [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2018 Nov;30(6):396-401. doi: 10.1097/CCO.0000000000000480.